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Apatite deposition in 
vascular calcification
Th ere is increasing interest in vascular 
calcifi cation in end-stage renal disease, as 
it has been demonstrated that it correlates 
with morbidity and mortality in this 
condition. Th e identity of the mineral that 
is deposited was studied in two animal 
models of this disease, one induced by 
adenine and a high-phosphate diet and 
the other induced by 5/6 nephrectomy in 
the presence of a high-phosphate diet and 
high-calcitriol treatment. Aortic sections 
were examined by synchrotron X-ray-
µ-fl uorescence and diff raction, by which 
all the minerals were examined. Atomic 
absorption was also used to estimate bulk 
calcium and magnesium. Th ree types of 
precipitates were seen: an amorphous 
precipitate, apatite, and a combination 
of apatite and magnesium-containing 
whitlockite. Th e occurrence of these 
precipitates diff ered signifi cantly between 
the two models. Furthermore, the 
combination of apatite and whitlockite 
was found exclusively in the calcitriol-
treated animals. Given that vitamin D 
stimulates not only calcium but also 
magnesium absorption in the intestine, 
these results suggest an explanation 
for the presence of whitlockite in these 
animals. Th e remarkable fi nding of these 
crystalline forms also raises the question 
of whether there are cells in the aortic 
wall capable of producing a crystalline 
precipitate, previously thought to occur 
largely in bone and in kidney stones. See 
page 298.
Cost of applying 
K/DOQI guidelines 
for phosphate control
In 2003, the National Kidney 
Foundation Kidney Disease Outcomes 
Quality Initiative (K/DOQI) published 
Clinical Practice Guidelines for the 
treatment of bone metabolism and 
disease in chronic kidney disease. Th ese 
guidelines advocated broad usage of 
non-calcium-based phosphate binders 
such as sevelamer. In this issue, a 
Canadian group estimates the cost of 
such treatment in a single dialysis unit 
and estimates what it would have cost 
to switch patients to sevelamer on the 
basis of the K/DOQI guidelines. Almost 
half of their 400-odd patients would 
qualify for the switch. Th e results are 
astounding. For this single hemodialysis 
unit, the cost of the switch was 
estimated to be about a half a million 
US dollars. Needless to say, a more 
compelling study would need to be 
designed before one could recommend 
wholesale switching from calcium-
based phosphate binders to sevelamer. 
See page 312.
Daily hemodialysis 
and phosphate control
Th e control of calcium and phosphate 
homeostasis in end-stage kidney disease 
is one of the more diffi  cult problems 
that face patients with this condition. 
As they report in this issue, Ayus et 
al. devised a controlled clinical trial 
in which they compared two groups 
of patients, one treated with daily 
hemodialysis for 3 hours per day 
6 days a week and the other treated in a 
more conventional manner with three 
4-hour sessions per week. Control of 
the serum phosphate was superior in 
those with daily dialysis aft er 1 year 
of treatment, as was the amount of 
phosphate removed during the dialysis. 
Th at group’s use of phosphate binders 
was also reduced. Many more patients 
on daily dialysis achieved their targets in 
mineral metabolism, such as reduction 
of phosphate and improvement in 
calcium or in parathyroid hormone 
levels. Other metabolic parameters 
were also improved, such as the daily 
protein catabolic rate. Th ese studies 
demonstrate a diffi  cult problem for 
the renal health-care system. Daily 
dialysis (not surprisingly) is superior to 
conventional hemodialysis, which raises 
the question: Now what do we do? See 
page 336.
Proteinuria and gene 
expression
Proteinuria is now thought to 
be itself the culprit in mediating 
tubulointerstitial disease and eventual 
progression to renal failure. To analyze 
the potential mechanisms by which 
these events occur, Rudnicki et al. 
performed microarray analysis on 
small identifi ed segments of proximal 
tubule removed by laser capture 
microdissection. Using as controls the 
normal sections of kidneys removed 
for renal-cell carcinoma, the authors 
compared the extracted RNA with that 
of proximal tubules microdissected 
from renal biopsies of patients with a 
variety of proteinuric states. Analysis 
of these microarrays showed 168 genes 
that were diff erentially expressed by 
the proteinuric proximal tubules. 
Th is included alterations in the 
Wnt signal-transduction pathways 
and upregulation of genes involved 
in cell proliferation and cell cycle 
control, cell diff erentiation, immune 
response, intracellular transport, and 
metabolism. Although these fi ndings 
showed some expected results, such 
as upregulation of profi brotic genes, 
they also showed that there was 
an increase in genes thought to be 
protective of tubules, such as BMP-7, 
providing a complex picture of disease-
causing genes being upregulated 
simultaneously with those that 
promote healing. See page 325.
